Eisai Sets Goal Of 45% Of Sales Outside Of Japan By 2002
Eisai aims to double sales outside of Japan within three years, Eisai U.S. President Soichi Matsuno told a recent Warburg Dillon Read analysts conference.
You may also be interested in...
Janssen/Eisai's proton pump inhibitor Aciphex (rabeprazole) is closing in on $250 mil. in sales after 13 months on the market, Eisai U.S. Chairman Soichi Matsuno indicated Oct. 3 at a UBS Warburg Global Life Sciences Conference in New York City.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011